<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>rgpv syllabus MPharm Non Grading System 0th Semester Pharmaceutical Analysis</title><meta name="author" content="HP"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: underline; font-size: 11.5pt; }
 h1 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 11.5pt; }
 .p, p { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11.5pt; margin:0pt; }
 .s2 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 11.5pt; }
 .s3 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s4 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 1; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
 li {display: block; }
 #l2 {padding-left: 0pt;counter-reset: d1 1; }
 #l2> li>*:first-child:before {counter-increment: d1; content: counter(d1, decimal)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l2> li:first-child>*:first-child:before {counter-increment: d1 0;  }
 li {display: block; }
 #l3 {padding-left: 0pt;counter-reset: e1 1; }
 #l3> li>*:first-child:before {counter-increment: e1; content: counter(e1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 #l3> li:first-child>*:first-child:before {counter-increment: e1 0;  }
 li {display: block; }
 #l4 {padding-left: 0pt;counter-reset: f1 1; }
 #l4> li>*:first-child:before {counter-increment: f1; content: counter(f1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11.5pt; }
 #l4> li:first-child>*:first-child:before {counter-increment: f1 0;  }
</style><!-- Basic Meta Tags -->
<meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta name="viewport" content="width=device-width,initial-scale=1" />

<!-- Page Title and Description -->
<meta name="description" content="Download and view the latest RGPV syllabus and timetable in PDF." />
<meta name="keywords" content="download, view, RGPV, syllabus, timetable, PDF" />

<!-- Robots Meta Tag -->
<meta name="robots" content="index, follow" />
<link rel="sitemap" href="/sitemap.xml" />

<!-- Twitter Meta Tags -->
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:title" content="RGPV Syllabus and Timetable" />
<meta name="twitter:description" content="Download and view the latest RGPV syllabus and timetable in PDF." />

<!-- Open Graph Meta Tags -->
<meta property="og:locale" content="en_IN" />
<meta property="og:type" content="website" />
<meta property="og:site_name" content="RGPV Syllabus and Timetable" />
<meta property="og:title" content="RGPV Syllabus and Timetable" />
<meta property="og:description" content="Download and view the latest RGPV syllabus and timetable in PDF." />

<!-- Other Tags -->
<link rel="prefetch" />
<meta name="audience" content="all" />
<meta name="rating" content="general" />
<meta name="generator" content="site" />
<meta name="google" content="translate" />
<meta name="theme-color" content="#4DBA87" />
<meta name="geo.placename" content="India" />
<meta name="revisit-after" content="1 days" />
<meta property="fb:admins" content="100012765211323" />
<meta name="apple-mobile-web-app-capable" content="no" />

<!-- Apple Touch Icon -->
<meta name="apple-mobile-web-app-title" content="www.rgpv-syllabus-timetable.in" />
<meta name="apple-mobile-web-app-status-bar-style" content="default" />
<link rel="apple-touch-icon" href="/img/icons/apple-touch-icon-152x152.png" />

<!-- Favicon and Icons -->
<link rel="mask-icon" href="/img/icons/safari-pinned-tab.svg" color="#4DBA87" />
<link rel="icon" type="image/png" sizes="32x32" href="/img/icons/favicon-32x32.png" />
<link rel="icon" type="image/png" sizes="16x16" href="/img/icons/favicon-16x16.png" />
<meta name="msapplication-TileImage" content="/img/icons/msapplication-icon-144x144.png" />

<!-- Search Engine Tags -->
<meta name="search engines" content="Aeiwi, Alexa, AllTheWeb, AltaVista, AOL Netfind, Anzwers, Canada, DirectHit, EuroSeek, Excite, Overture, Go, Google, HotBot, InfoMak, Kanoodle, Lycos, MasterSite, National Directory, Northern Light, SearchIt, SimpleSearch, WebsMostLinked, WebTop, What-U-Seek, AOL, Yahoo, WebCrawler, Infoseek, Excite, Magellan, LookSmart, CNET, Googlebot" />

<!-- Pingback and OpenID -->
<link rel="pingback" href="https://www.rgpv-syllabus-timetable.in/" />
<link rel="openid.delegate" href="https://www.rgpv-syllabus-timetable.in/" />

<!-- Content Type -->
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<body><div style="display:flex;justify-content:flex-end;"><a href="#" target="_blank" download="" id="pdf-download-link"><button type="button" style="cursor:pointer;-webkit-appearance:button;color:#fff;background-color:#007bff;border-color:#007bff;display:inline-block;font-weight:400;text-align:center;white-space:nowrap;vertical-align:middle;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;border:1px solid transparent;padding:0.375rem 0.75rem;font-size:1rem;line-height:1.5;border-radius:0.25rem;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;text-transform:none;overflow:visible;margin:0;font-family:inherit;" download>Download PDF</button></a></div><script>const a=(window.location.pathname).split("/");const filename="" + a[a.length-1] + ".pdf";document.getElementById("pdf-download-link").href=filename;</script><p class="s1" style="padding-left: 126pt;text-indent: 0pt;text-align: center;">MPY 301 (Pca) : IMPURITY PROFILING</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit I</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Introduction: C<span class="p">lassification of impurities in pharmaceutical products, origin of impurities, types of impurities: process impurities, degradation impurities, and contamination impurities. Nature of impurities: organic, inorganic, and residual solvent impurities. Differences between impurities and degradation products. Pharmacopoeial limits of impurities in drug substance and drug products.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit II</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Application of hyphenated characterization techniques in impurity profiling: <span class="p">LC-MS, LC- MS-MS, GC-MS, TLC-MS, CE-MS, MEKC-MS, CEC-MS, LC-NMR, LC-IR etc.</span></h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Toxicological perspectives of impurities in pharmaceutical products: <span class="p">Classes of genotoxic impurity, analytical challenge of genetic toxins, determination of genotoxic impurities.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit III</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Application  of  analytical  techniques  in  impurity  profiling:  <span class="p">Chromatography:  HPLC, preparative  chromatography,  flash  chromatography,  column  chromatography,  gas chromatography; Spectroscopy: UV/Visible, FTIR, Raman, NIR, MS, and NMR spectroscopy; Electrophoretic  and  Related  Methods:  Capillary  electrophoresis,  micellar  electrokinetic chromatography  (MEKC),  microemulsion  electrokinetic  chromatography  (MEEKC)  and capillary electrochromatography (CEC).</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit IV</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Impurity identification &amp; structure elucidation: <span class="p">Introduction of systematic approaches for isolation, identification, and structure elucidation of unknown impurities. Case studies for impurity identification and structure ilucidation. Setting of limits for impurities in drug products.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit V</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Regulatory requirements of impurity profiling<span class="p">: ICH guidelines, EMEA guideline, PhRMA approach, USFDA guidance, European pharmacopoeial guidance, Guidance for oncology products, Identification, qualification, and quantification threshold of impurities, Regulatory perspective of impurities for different New Drug Applications (NDA).</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Books and references recommended:</h1><ol id="l1"><li data-list-text="1."><p style="padding-left: 39pt;text-indent: -17pt;line-height: 13pt;text-align: left;">R.J. Smith, M. L. Webb, <i>Analysis of drug impurities, </i>Blackwell Publishing.</p></li><li data-list-text="2."><p style="padding-left: 40pt;text-indent: -17pt;text-align: left;">M. V. N. Kumar Talluri, <i>Impurity profiling of drugs and pharmaceuticals, </i>Lambert Academic Publishing.</p></li><li data-list-text="3."><p style="padding-left: 39pt;text-indent: -17pt;line-height: 13pt;text-align: left;">ICH harmonized tripartite guideline, <i>Impurities in new drug products Q3B(R2)</i></p></li><li data-list-text="4."><p style="padding-left: 39pt;text-indent: -17pt;text-align: left;">ICH harmonized tripartite guideline<i>, Impurities: guideline for residual solvents Q3C(R3)</i></p></li><li data-list-text="5."><p style="padding-left: 39pt;text-indent: -17pt;text-align: left;">USFDA, Guidance for Industry ANDAs: <i>Impurities in drug products.</i></p></li><li data-list-text="6."><p style="padding-left: 39pt;text-indent: -17pt;text-align: left;">USFDA, Guidance for Industry ANDAs: <i>Impurities in drug substances.</i></p></li><li data-list-text="7."><p class="s2" style="padding-left: 39pt;text-indent: -17pt;text-align: left;">United states pharmacopoeia<span class="p">.</span></p></li></ol><p class="s1" style="padding-left: 26pt;text-indent: 0pt;text-align: left;">MPY 302 (Pca) : BIOANALYTICAL METHODS &amp; METABOLITE PROFILING</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit I</h1><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><b>Role of drug metabolism research in drug discovery: </b>Types of metabolites, assessment of potential toxicity of metabolites, metabolic clearance in body. Study of detailed procedure of i<i>n- vitro </i>drug metabolism studies, <i>in-vivo </i>ADME studies. Impact of metabolic information in investigational new drug application (IND) and new drug application (NDA).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit II</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Liquid radiochromatography techniques: <span class="p">Introduction, instrumentation, and application of new radiochromatography techniques in drug metabolism studies: HPLC-RFD, HPLC-LSC, HPLC-MSC, Stop-Flow HPLC-RFD, dynamic flow HPLC-RFD, UPLC-radiodetection, HPLC- AMS, LC-RFD-MS, stop-flow and dynamic flow LC–RFD–MS, LC-MSC-MS. Profiling of radiolabeled metabolites in plasma, analysis of metabolites of nonradiolabeled drugs using radiolabeled cofactors or trapping agents, determination of structures and formation pathways of sequential metabolites, enzyme kinetic studies.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit III</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Metabolite identification &amp; structure determination: <span class="p">Application of various analytical techniques for improving metabolite detection and identification, software-assisted metabolite identification, MS-related techniques for metabolite identification, characterization of unstable metabolites, detection and characterization of reactive metabolites and intermediates, examples of metabolite structure determination from known biotransformations.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit IV</h1><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><b>Common experimental approaches &amp; protocols: </b>Metabolic stability, characterization of enzyme kinetics, quantitative analytical methods, prediction of human hepatic clearance, protocols for assessment of in-vitro &amp; in-vivo bioactivation potential of drug candidates, reaction phenotyping,  analysis  of  <i>in-vitro  </i>cytochrome  P450  inhibition  in  drug  discovery  and development, testing drug candidates for CYP3A4 induction.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit V</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">ADME studies in animals and humans<span class="p">: Objectives, rational, and regulatory compliance, experimental  design,  sample  analysis,  metabolite  profiling  and  identification,  and  data presentation, examples of data presentation. Bioanalytical method development &amp; validation.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Books and references recommended:</h1><ol id="l2"><li data-list-text="1."><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Donglu Zhang, Mingshe Zhu, W. Griffith Humphreys<i>; Drug Metabolism in Drug Design and Development, </i>Wiley Interscience.</p></li><li data-list-text="2."><p style="padding-left: 18pt;text-indent: -13pt;line-height: 13pt;text-align: left;">Roger M. Smith; <i>Handbook of analytical separations: Bioanalytical Separation, Volume 4,</i></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Elsevier Sciences Publication.</p></li><li data-list-text="3."><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;">D. A. Welis: <i>High throughput bioanalytical sample preparation: Methods and automation strategies, </i>Elsevier Sciences Publication.</p></li><li data-list-text="4."><p style="padding-left: 18pt;text-indent: -13pt;text-align: left;">Sarfaraz K. Niazi; <i>Handbook of Bioequivalence Testing, </i>Informa Healthcare.</p></li></ol><p class="s1" style="padding-left: 35pt;text-indent: 0pt;text-align: left;">MPY 303 (Pca) : QUALITY CONTROL TESTING OF HERBAL PRODUCTS</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Unit I</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Evaluation of herbal drugs: <span class="p">Concept, considerations, parameters and methods of quality control for medicinal plant materials as per different pharmacopoeias and other guidelines. Regulations of ayurvedic pharmacopoeia of India, Ayurvedic formulary of India, and WHO guidelines with respect to herbal product testing.</span></h1><h1 style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit II</h1><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;"><b>Quantitative and qualitative testing of herbal products: </b>Microscopic identification, foreign matter, ash, extractive, moisture content (LOD), Volatile oil in drugs. Determination of refractive index, specific gravity, <i>p</i>H value, melting and congealing range, boiling range, optical rotation, viscosity, total solids, solubility, saponification value, iodine value, acid value, peroxide value, unsaponifiable matter, mineral oil (Holde’s test), rancidity test (Kreis test), alcohol content.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Methods of estimation of starch, fatty oil, protein, alkaloid, pesticide residues, aflatoxin, total phenolics,  total  tannins,  reducing  sugars,  total  sugars,  non-reducing  sugars,  curcumin, densitometer, aluminium, borax, calcium, copper, iron, magnesium, mercury, silica, sodium and potassium, sulphur. Limit tests, microbial limit tests.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit III</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Application of chromatographic techniques: <span class="p">Separation and identification of herbal products. Application of UV, IR, NMR, 1H NMR, 13C NMR &amp; Mass spectroscopy data for purification and  structure  elucidation  of  phytoconstituents.  Herbal  fingerprint  profile  of  single  and multicomponent  herbal  drugs.  Stability testing  of  natural  products.  Isolation  of  marker compound and their characterization.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit IV</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Analysis of ayurvedic formulations and crude drugs: <span class="p">Identity, purity, and quality of crude drugs.  Determination of pesticide  residues,  determination  of  arsenic  and  heavy metals, determination of microbial load in crude drugs. Identification of aflatoxins in crude drugs. Quantitative microscopy, including lycopodium spore method as applied to drug evaluation and pollen grain analysis.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit V</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Regulatory requirements: <span class="p">Importance of crude drug standardization and application of biomarkers. Standardization, quality, efficacy and safety requirements &amp; assessment procedures for  herbal  medicines  as  per  USFDA.  Guidelines  on  quality  of  herbal  medicinal products/traditional herbal medicinal products, test procedures and acceptance criteria for herbal medicinal products as per EMEA requirements.</span></h1><h1 style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: justify;">Books and references recommended:</h1><ol id="l3"><li data-list-text="1."><p class="s3" style="padding-left: 22pt;text-indent: -17pt;text-align: left;">P. Houghton, P. K. Mukherjee, <i>Evaluation of Herbal Medicinal Products Perspectives on quality, safety and efficacy, </i>Pharmaceutical Press.</p></li><li data-list-text="2."><p class="s3" style="padding-left: 22pt;text-indent: -17pt;line-height: 11pt;text-align: left;">P. K. Mukherjee, <i>Quality control of herbal drugs: an approach to evaluation of botanicals, </i>Business Horizons.</p></li><li data-list-text="3."><p class="s3" style="padding-left: 22pt;text-indent: -17pt;text-align: left;">European Medicines Agency (EMEA), evaluation of medicines for human use: <i>Guidance on Herbal products.</i></p></li><li data-list-text="4."><p class="s4" style="padding-left: 22pt;text-indent: -17pt;text-align: left;">The Ayurvedic Pharmacopoeia of India, First edition, <span class="s3">Government of India Ministry of Health And Family Welfare Department of Ayush, 2007.</span></p></li></ol><p class="s1" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">MPY 304 (Pca) : STABILITY TESTING OF DRUG SUBSTANCES &amp; DRUG PRODUCTS</p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit I</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">ICH and WHO stability guidelines: <span class="p">Stress testing, Selection of batches, container and closures system,  specification,  testing  frequency,  storage  conditions,  Stability  commitments  and evaluation. Photostability testing conditions and procedures.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit II</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Stress testing program: <span class="p">Approches and conditions for stress testing i.e temperature, humidity, pH etc. Possible drug degradation pathways, Generic approach for stress testing. Reporting and documentation. Protocols for stress testing program of a drug substances and drug product.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit III</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Stability prediction: A<span class="p">pplications of Arrhenius theory for stability prediction, activation energy calculation and its application in shelf life prediction, Q10 value calculation. Shelf life determination, calculation of overages.</span></h1><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit IV</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Statistical and regulatory aspect of drug stability studies: <span class="p">Current regulations and guidance, statistical model building, evaluating stability batches. Matrixing and bracketing designs for stability studies. Overview on reduction of testing plans. Variations and changes in stability conditions in India, ASEAN, Arab countries, Brazil and Europe. Stability variations. Extention of retest date and its data requirements. Postapproval FDA stability requirements.</span></h1><h1 style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;line-height: 13pt;text-align: left;">Unit V</h1><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Physical stability testing: <span class="p">Requirement, study parameters, and applications of physical stability testing for tablets, dispersed systems, semisolids and liquid dosage forms.</span></h1><p style="padding-top: 11pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Preservatives stability studies: Assesment of preservative activity, test design, efficacy testing, factors influencing reproduceability. Pharmacopoeial methods, acceptance criteria.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Books and references recommended:</h1><ol id="l4"><li data-list-text="1."><p class="s2" style="padding-top: 11pt;padding-left: 22pt;text-indent: -17pt;text-align: left;">Q1 Stability, <span class="p">ICH Guidelines.</span></p></li><li data-list-text="2."><p style="padding-left: 22pt;text-indent: -17pt;text-align: left;">David J. Mazzo, <i>International stability testing</i>, Interpharm Press.</p></li><li data-list-text="3."><p style="padding-left: 22pt;text-indent: -17pt;text-align: left;">L. Lachman, H. A. Lieberman, J. L. Kanig, <i>The theory and practice of industrial pharmacy.</i></p></li><li data-list-text="4."><p style="padding-left: 22pt;text-indent: -17pt;text-align: left;">J. T. Carstensen, C. T. Rhodes, <i>Drug stability: principles and practices</i>, Informa Healthcare.</p></li><li data-list-text="5."><p style="padding-left: 22pt;text-indent: -17pt;text-align: left;">Kim Huynh-Ba, <i>Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices, </i>Springer.</p></li><li data-list-text="6."><p style="padding-left: 22pt;text-indent: -17pt;line-height: 13pt;text-align: left;">Banker and Rhodes, <i>Modern pharmaceutics, </i>Marcel Dekker<i>.</i></p></li><li data-list-text="7."><p class="s2" style="padding-left: 22pt;text-indent: -17pt;text-align: left;">Remington’s pharmaceutical sciences.</p></li><li data-list-text="8."><p class="s2" style="padding-left: 22pt;text-indent: -17pt;text-align: left;">United states pharmacopoeia<span class="p">.</span></p></li></ol></body></html>
